SMITH+NEPHEW ADR5 DL-20/2
SMITH+NEPHEW ADR5 DL-20/2
Depository Receipt · US83175M2052 · SNN · 939163 (XNYS)
Overview
30,30 USD
0,46 % 0,14 USD
NYSE (XNYS) · Current prices and charts at MoneyPeak
21.07.2025 10:06

Current Prices from SMITH+NEPHEW ADR5 DL-20/2

ExchangeTickerCurrencyLast TradePriceDaily Change
XNYS: NYSE
NYSE
SNN
USD
21.07.2025 10:06
30,30 USD
0,14 USD
+0,46 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
0,46 % 2,71 % 5,12 % 16,85 % 19,76 % 7,10 % -27,22 %

Company Profile for SMITH+NEPHEW ADR5 DL-20/2 Depository Receipt

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Company Data

Name SMITH+NEPHEW ADR5 DL-20/2
Company Smith & Nephew plc
Symbol SNN
Website https://www.smith-nephew.com
Primary Exchange XNYS NYSE
WKN 939163
ISIN US83175M2052
Asset Class Depository Receipt
Sector Healthcare
Industry Medical - Devices
CEO Dr. Deepak S. Nath Ph.D.
Market Capitalization 13 Mrd.
Country United Kingdom
Currency USD
Employees 17,3 T
Address Building 5, WD18 8YE Watford
IPO Date 1999-11-16

Stock Splits

Date Split
15.10.2014 2499:1000
16.12.2003 2:1
07.08.2000 9:11

Ticker Symbols

Name Symbol
Frankfurt NPWA.F
NYSE SNN

More Shares

Investors who SMITH+NEPHEW ADR5 DL-20/2 hold also have the following shares in their portfolio:
AUST.PAC.AIR 21/31
AUST.PAC.AIR 21/31 Bond
SABINE PASS LIQ.2023
SABINE PASS LIQ.2023 Bond
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025